Table 4.
Cox proportional hazards model analysis of multi-variables in survival for CRC patients.
| Variables | Categories | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | ||
| Sex | Male vs. Female | 0.983 (0.667–1.427) | 0.927 | ||
| Age (years) | >66 vs. ≤ 66 | 1.060 (0.733–1.534) | 0.756 | ||
| Tumor status | T3+4 vs. T1+2 | 2.504 (1.512–4.147) | <0.001 | 1.793 (1.059–3.035) | 0.030 |
| Nodal status | N1+2 vs. N0 | 3.064 (2.062–4.554) | <0.001 | 0.919 (0.107–7.921) | 0.919 |
| Metastasis status | M1 vs.M0 | 2.009 (0.881–4.580) | 0.097 | 1.047 (0.419–2.612) | 0.922 |
| Clinical stage | III+IV vs. I+II | 3.142 (2.108–4.683) | <0.001 | 2.913 (0.322–26.34) | 0.341 |
| HLA-G (mAb 4H84) | Pos vs. Neg | 1.267 (0.830–1.933) | 0.272 | ||
| HLA-G (mAb 5A6G7) | Pos vs. Neg | 0.812 (0.561–1.175) | 0.270 | ||
| ΔHLA-G status* | ΔHLA-G neg vs. ΔHLA-G com+pos | 0.414 (0.216–0.792) | 0.008 | 0.416 (0.217–0.798) | 0.008 |
HR, hazard ratio; 95% CI = 95% confidence interval.
*
ΔHLA-G: the difference of the percentage of HLA-G expression detected with mAb 4H84 subtracted that with mAb 5A6G7. ΔHLA-Gneg:ΔHLA-G > −5.0%; ΔHLA-Gcom: −5.0%≤ΔHLA-G≤5.0%; ΔHLA-Gpos: ΔHLA-G > 5.0%.